InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.03
(
-0.55%
)
Bitcoin
54,770.60
(
-1.93%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

vidpok45

Send PM Follow Ignore
Followers 0
Posts 4859
Boards Moderated 0
Alias Born 06/15/2010

vidpok45

Re: rurik post# 55756

Monday, 11/03/2014 12:11:03 PM

Monday, November 03, 2014 12:11:03 PM

Post# of 80490
Based on the Tasigna study, a ten percent dose of Ponatinib of 10mg may be sufficient especially as Ponatinib is stronger than Tasigna. It is feasible that this low dosage may mitigate the SAEs. For Berger not to pursue this indication because of possible SAEs would be just another reason we need a change of leadership. I hope Denner will push a partnership for this incredibly lucrative indication.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up